Biopharma Daily Stock Updates - 06/07/22

Table of Contents:

#NVAX 0.0% (+22% AH) Novavax Statement on Stock Trading Halt; FDA Advisory Committee to Review Novavax’ COVID-19 Vaccine.

#NVAX 0.0% (+22% AH) FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older

#VERU +16.8% Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients at High Risk for ARDS

#DBVT -1.9% (+29.4% AH) DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in Peanut-Allergic Toddlers

#MCRB +28.8% Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection.

#ANNX +24.9% Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease.

#BLUE +21.2% bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting.

#ALDX +12.2% Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease

#CVM +9.1% CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO

#CNCE +6.1% Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology.

#APLS +4.6% Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need.

#ASND +4.6% Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for TransCon™ PTH to be a Replacement Therapy for Adult Hypoparathyroidism at ENDO 2022.

#MRNA +3.8% Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010).

#BCRX +3.7% BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic.

#JAZZ +3.6% Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting.

#HALO +3.5% Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy.

#ALVR +3.1% AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients.

#TALS +0.1% Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022

#ASLN -2.4% ASLAN Pharmaceuticals Initiates Scientific Collaboration to Investigate the Distinct Role of IL-13 Receptor Signaling in Atopic Dermatitis.

#PMVP -21.7% PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation

Want to get weekly catalyst updates?

*We never spam you - unsubscribe anytime*

#EIGR -0.8% Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital Partners to Refinance Existing Debt Facility and Further Strengthen Cash Position Ahead of Key Milestones

Posted by FS/JM